UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934
For the Month of: August 2017
Commission File Number: 001-37847
MOTIF BIO PLC
(Exact name of registrant as specified in its charter)
125 Park Avenue
25th Floor
New York, New York 10011
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F x Form 40-F o
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): o
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): o
MOTIF BIO PLC
FORM 6-K
MOTIF BIO TO PRESENT AT UPCOMING INVESTOR AND SCIENTIFIC CONFERENCES
On August 31, 2017, Motif Bio plc (the Company) issued a press release, a copy of which is attached as Exhibit 99.1 to this report on Form 6-K, announcing that the Company will present at the following two conferences in September 2017: (1) the Rodman & Renshaw 19th Annual Global Investment Conference on Monday, September 11, 2017 in New York, New York and (2) the World Anti-Microbial Resistance Congress on September 15, 2017 in Washington, D.C.
The information contained in Exhibit 99.1 is being furnished to the U.S. Securities and Exchange Commission (the Commission) and shall not be deemed incorporated by reference into any of the registrants registration statements or other filing with the Commission.
Exhibits
Exhibit 99.1 Press release issued by Motif Bio plc, dated August 31, 2017, entitled Motif Bio to present at upcoming investor and scientific conferences.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
|
MOTIF BIO PLC | |
|
| |
|
By: |
/s/ Robert Dickey IV |
|
Name: Robert Dickey IV | |
|
Title: Chief Financial Officer |
Date: August 31, 2017
Exhibit 99.1
31 August 2017
Motif Bio plc
(Motif or the Company)
Motif Bio to present at upcoming investor and scientific conferences
Motif Bio plc (AIM/NASDAQ: MTFB), the clinical stage biopharmaceutical company specialising in developing novel antibiotics, announced today that the Company will present at the following conferences in September.
Rodman & Renshaw 19th Annual Global Investment Conference
September 10-12, 2017
New York, NY USA
Management will provide a corporate overview on Monday, September 11th at 11:15 AM ET. The presentation will be webcast, available live, and as a replay in the Investors section of the Companys website.
The conference is expected to feature approximately 200 public and private companies presenting their businesses to an audience of approximately 2,000 attendees. Motif will also participate in one-on-one meetings during the event.
World Anti-Microbial Resistance Congress
September 14-15, 2017
Washington, DC USA
David Huang, MD, PhD, Chief Medical Officer of Motif Bio, will deliver the luncheon keynote address on September 15th. His talk is entitled: Iclaprim: a well differentiated, targeted, potent and rapidly bactericidal antibiotic against multidrug resistant bacteria.
The congress provides a platform for change on both the scientific and economic sides of the antimicrobial resistance space, bringing the leaders from each area together to take steps toward finding collaborative solutions that optimize the best of both worlds. The event gathers key stakeholders from government, funding agencies, pharma, academia, hospitals, and payers.
For further information please contact:
Motif Bio plc |
|
info@motifbio.com |
Graham Lumsden (Chief Executive Officer) |
|
|
Robert Dickey IV (Chief Financial Officer) |
|
|
|
|
|
Walbrook PR Ltd. (FINANCIAL PR & IR) |
|
+44 (0) 20 7933 8780 or motifbio@walbrookpr.com |
Paul McManus |
|
Mob: +44 (0)7980 541 893 |
Mike Wort |
|
Mob: +44 (0)7900 608 002 |
|
|
|
MC Services AG (EUROPEAN IR) |
|
+49 (0)89 210 2280 |
Raimund Gabriel |
|
raimund.gabriel@mc-services.eu |
|
|
|
The Trout Group (US IR) |
|
+1 (646 )378-2938 |
Michael Gibralter |
|
mgibralter@troutgroup.com |
Notes to Editors
About Motif Bio
Motif Bio plc (AIM/NASDAQ: MTFB) is a clinical-stage biopharmaceutical company engaged in the research and development of novel antibiotics designed to be effective against serious and life-threatening infections in hospitalised patients caused by multi-drug resistant bacteria, including MRSA (methicillin-resistant Staphylococcus aureus). The Companys lead product candidate, iclaprim, is being developed for high-risk MRSA patient populations. The first proposed indication, and near-term commercial opportunity, is for the treatment of acute bacterial skin and skin structure infections (ABSSSI), one of the most common bacterial infections, with 3.6 million patients hospitalised annually in the U.S. The Company believes that iclaprim is suitable for first-line empiric therapy in ABSSSI patients, especially those with renal impairment, with or without diabetes, due to its underutilised mechanism of action, targeted spectrum of activity, low propensity for resistance development, fixed dose administration, clearance of inactive metabolites through the kidneys and favourable tolerability profile. The Company also plans to develop iclaprim for hospital acquired bacterial pneumonia (HABP), including ventilator associated bacterial pneumonia (VABP), as there is a high unmet need for new therapies in this indication and iclaprim has demonstrated initial evidence of efficacy in a Phase 2 trial in patients with HABP. Additionally, in a clinical study evaluating the tissue distribution of an IV dose of Iclaprim in relevant lung compartments, high concentrations were found in epithelial lining fluid and alveolar macrophages, achieving levels up to 20- and 40-fold higher, respectively, than in plasma. Iclaprim has been studied in an animal model of chronic pulmonary MRSA infection which mimics the pathophysiology observed in patients with cystic fibrosis. Data will be presented at ID Week in October 2017. Iclaprim has received Qualified Infectious Disease Product (QIDP) designation from the FDA together with Fast Track status. Upon acceptance of the NDA, iclaprim will receive Priority Review status and, if approved as a New Chemical Entity, will be eligible for 10 years of market exclusivity in the U.S. from the date of first approval under the Generating Antibiotic Incentives Now Act (the GAIN Act). In Europe, 10 years of data exclusivity is anticipated.
Forward-Looking Statements
This press release contains forward-looking statements. Words such as expect, believe, intend, plan, continue, may, will, anticipate, and similar expressions are intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other important factors that may cause Motif Bios actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Motif Bio believes that these factors include, but are not limited to, (i) the timing, progress and the results of clinical trials for Motif Bios product candidates, (ii) the timing, scope or likelihood of regulatory filings and approvals for Motif Bios product candidates, (iii) Motif Bios ability to successfully commercialise its product candidates, (iv) Motif Bios ability to effectively market any product candidates that receive regulatory approval, (v) Motif Bios commercialisation, marketing and manufacturing capabilities and strategy, (vi) Motif Bios expectation regarding the safety and efficacy of its product candidates, (vii) the potential clinical utility and benefits of Motif Bios product candidates, (viii) Motif Bios ability to advance its product candidates through various stages of development, especially through pivotal safety and efficacy trials, (ix) Motif Bios estimates regarding the potential market opportunity for its product candidates, and (x) the factors discussed in the section entitled Risk Factors in Motif Bio plcs Annual Report on Form 20-F filed with the SEC on May 1, 2017, which is available on the SECs web